Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-64041757 in advanced NSCLC
NCT02592967Phase 1Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2015
- Primary completion
- Aug 2018
- Modality
- Oncolytic Viruses, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of Pemlimogene merolisbac in non-small cell lung cancer (NSCLC) (4 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Incidence of Dose-limiting toxicity at 21 days, Antigen-specific T-cell Response at 1 year and 1 more. Started Dec 2015; status: terminated.
02
Drugs
Pemlimogene merolisbac
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02592967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02592967.